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Abstract
Purpose Zoledronic acid (ZA) or denosumab treatment reduces
skeletal-related events; however, the safety of prolonged therapy
has not been adequately studied. Here, we describe safety results
of extended denosumab therapy in patients with bonemetastases
from the open-label extension phase of two phase 3 trials.
Methods Patients with metastatic breast or prostate cancer re-
ceived subcutaneous denosumab 120 mg Q4Wor intravenous
ZA 4 mgQ4W in a double-blinded fashion. Denosumab dem-
onstrated superior efficacy in the blinded treatment phase;
thus, patients were offered open-label denosumab for up to
an additional 2 years.
Results Cumulative median (Q1, Q3) denosumab exposure
was 19.1 (9.2, 32.2) months in the breast cancer trial
(n = 1019) and 12.0 (5.6, 21.3) months in the prostate cancer
trial (n = 942); 295 patients received denosumab for >3 years.
No new safety signals were identified during the open-label
phase, or among patients who switched from ZA to
denosumab. During the blinded treatment phase, exposure-
adjusted subject incidences of osteonecrosis of the jaw
(ONJ) were 49 (1.9 %) and 31 (1.2 %) in the denosumab
and ZA groups, respectively. In total, 32 (6.9 %) and 25
(5.5 %) new cases of ONJ (not adjusted for exposure) were
reported for patients continuing and switching to denosumab,
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respectively. The incidences of hypocalcemia were 4.3 and
3.1 %, in patients continuing and switching to denosumab,
respectively.
Conclusion These results describe the safety profile of
denosumab after long-term exposure, or after switching to
denosumab from ZA. No new safety signals were identified.
Hypocalcemia rates were similar in the blinded treatment and
open-label phases. ONJ rates increased with increasing expo-
sure to antiresorptives, consistent with previous reports.
Keywords Bonemetastases . Breast cancer . Denosumab .
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Introduction
Patients with metastatic cancer are living longer and with im-
proved quality of life [1]. Bone-targeted therapies for
preventing skeletal-related events (SREs: fracture, spinal cord
compression, and radiation or surgery to bone) are an integral
component of care in the treatment of patients with bone me-
tastases; and their use for longer durations seems warranted to
prevent SREs, provided that the benefit is not outweighed by
safety considerations.
Denosumab (XGEVA®, Amgen Inc. Thousand Oaks, CA,
USA), a fully human monoclonal antibody directed against re-
ceptor activator of nuclear factor kappa-B (RANK) ligand, has
been approved for preventing SREs in patients with solid tumors
based on results from three international double-blind, active-
controlled phase 3 trials comprising over 5700 patients [2]. Re-
sults from the two trials involving patients with breast and pros-
tate cancers demonstrated superiority of denosumab compared
with zoledronic acid (ZA) (Zometa®, Novartis Pharmaceuticals
Corporation, East Hanover, NJ, USA) for prevention of SREs.
Consequently, patients were offered open-label denosumab for a
period of up to 2 additional years once the results of the primary
analysis were achieved.We now describe the safety results from
long-term administration of denosumab in these two studies,
including in patients previously treated with ZA.
Methods
Patients
Adults with breast or castration-resistant prostate cancer and
radiographic evidence of at least one bone metastasis were
enrolled as previously described [3, 4]. Both studies were
conducted according to the Helsinki Declaration and the In-
ternational Conference on Harmonization of Good Clinical
Practice guidelines. Approvals from appropriate research
ethics committees were obtained from each study center, and
all patients provided written informed consent.
Treatment
In the double-blinded treatment phase, patients were random-
ized to receive subcutaneous (SC) denosumab (120 mg every
4 week (Q4W)) plus intravenous (IV) placebo or SC placebo
plus IV ZA (4 mg Q4W) (Fig. 1). Following the positive
results of the primary analysis, the patients were offered con-
tinued treatment with denosumab for up to 2 additional years
during an open-label extension treatment phase. Patients ini-
tially randomized to denosumab during the blinded treatment
phase (denosumab/denosumab group) continued to receive
denosumab at 120 mg Q4W. Patients initially randomized to
ZA during the blinded phase and then switched to denosumab
in the open-label phase (ZA/denosumab group) were treated
with denosumab at 120 mg Q4W starting 4 weeks from their
last ZA dose. Patients who declined further therapy in the
open-label extension phase, or who did not complete the
blinded treatment phase, continued follow-up for survival ev-
ery 12 weeks (Q12W) for up to 2 years after their last dose in
the blinded treatment phase.
Safety outcomes
Adverse events were monitored and potential osteonecrosis of
the jaw (ONJ) events were adjudicated by an independent
committee of dentists and oral surgeons [4]. ONJ rates were
calculated as a ratio of the total number of adjudicated positive
ONJ events and the total patient-years of follow-up, as pa-
tients were treated for different lengths of time. Eligible pa-
tients who enrolled in the open-label phase of the trials and
received at least one dose of open-label denosumab were in-
cluded in the safety analyses.
Results
Following the blinded portion of the trials, nearly 90 % of
eligible patients chose to continue or switch to denosumab
therapy, including 667 breast cancer patients (325 and 342
initially randomized to denosumab and ZA, respectively)
and 281 prostate cancer patients (153 and 128 randomized,
respectively). Patient demographics (Table 1) were similar to
those of the entire trial populations [3, 4].
Drug exposure
Among patients initially randomized to denosumab, cumula-
tive median denosumab exposures (including blinded and
open-label treatment phases) were slightly greater in the breast
cancer study compared with the prostate cancer study
(Table 2). Maximal exposures for patients in the denosumab/
denosumab group were up to 5 years in the breast cancer study
and up to 5.6 years in the prostate cancer study. Prior to
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switching to open-label denosumab, the median (Q1, Q3)
(range) exposures to ZA during the double-blinded treatment
phase for all randomized patients were 18.4 (9.1, 24.9)
(0.3–39.6) months in the breast cancer study and 10.2
(4.9, 17.8) (0–41.6) months in the prostate cancer study.
Among patients who continued on the open-label phase,
median (Q1, Q3) (range) ZA exposures were 19.6 (9.8,
25.0) (0–38.6) months and 11.2 (5.7, 19.4) (0–41.3)
months, respectively. Across all phases of both studies,
295 patients received monthly denosumab for ≥3 years.
In the breast cancer study, 216 and 76 patients received
therapy for ≥3 and for ≥4 years, respectively; 79 and 29
patients received therapy for ≥3 and for ≥4 years, re-
spectively, in the prostate cancer study.
Safety
Overall, 652 breast cancer patients (318 and 334 initially ran-
domized to denosumab and ZA, respectively) and 265 pros-
tate cancer patients (147 and 118 initially randomized to
denosumab and ZA, respectively) received at least one dose
of denosumab during the open-label treatment phase
(Table 3). No new safety signals were observed during the
open-label extension phase. No neutralizing anti-denosumab
Fig. 1 Study design and treatment schema, SC subcutaneous, IV intravenous, Q4W every 4 weeks
Table 1 Selected patient characteristics at entry to open-label study phase
Characteristic Breast cancer study Prostate cancer study
Denosumab/
Denosumab
(n = 325)
Zoledronic Acid/
Densoumab
(n = 342)
Denosumab/
Denosumab
(n = 153)
Zoledronic Acid/
Denosumab
(n = 128)
Age (years) median [Q1, Q3] 56.0 [48.0, 64.0] 55.9 [48.0, 65.0] 70.0 [66.0, 77.0] 71.0 [66.0, 75.5]
Age group, n (%)
≥65 years 74 (22.8) 86 (25.1) 121 (79.1) 98 (76.6)
≥75 years 17 (5.2) 19 (5.6) 52 (34.0) 41 (32.0)
ECOG performance status, n (%) (n = 299) (n = 303) (n = 139) (n = 116)
0 or 1 288 (96.3) 287 (94.7) 124 (89.2) 102 (87.9)
≥2 11 (3.7) 16 (5.3) 15 (10.8) 14 (12.1)
BPI-SF pain severity, n (%) (n = 325) (n = 342) (n = 153) (n = 128)
No pain (0) 71 (21.8) 62 (18.1) 38 (24.8) 28 (21.9)
Mild (1–4) 143 (44.0) 158 (46.2) 66 (43.1) 49 (38.3)
Moderate (5–6) 39 (12.0) 49 (14.3) 21 (13.7) 18 (14.1)
Severe (7–10) 43 (13.2) 46 (13.5) 17 (11.1) 19 (14.8)
Missing 5 (1.5) 4 (1.2) 0 (0.0) 1 (0.8)
Creatinine clearance (mL/min), n (%) (n = 318) (n = 334) (n = 147) (n = 118)
15 to <30 1 (0.3) 0 (0.0) 3 (2.0) 5 (4.2)
30 to <60 31 (9.7) 48 (14.4) 28 (19.0) 24 (20.3)
60 to >90 103 (32.4) 101 (30.2) 52 (35.4) 43 (36.4)
≥90 168 (52.8) 162 (48.5) 59 (40.1) 39 (33.1)
Missing 15 (4.7) 23 (6.9) 5 (3.4) 7 (5.9)
Q1, Q3 first and third quartiles, ECOG Eastern Cooperative Oncology Group, BPI-SF Brief Pain Inventory-Short Form
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antibodies were detected. Rates of adverse events and serious
adverse events were similar to those seen during the studies’
blinded treatment phases. Adverse events were generally bal-
anced between treatment groups independent of whether pa-
tients were initially randomized to denosumab or ZA during
the blinded phase of the study (Table 3).
In the blinded phase, adverse events of infection were re-
ported by similar percentages of patients in both treatment
groups [3, 4]. Adverse events of infection overall occurred
in approximately 40% of patients during the open-label phase
(Table 3). The most common infections observed were
nasopharyngitis, urinary tract infections, and influenza in the
breast cancer study and urinary tract infect ions,
nasopharyngitis, and pneumonia in the prostate cancer study.
Overall, the incidences of infectious events were generally
similar to those observed in the blinded treatment phases for
each study.
During the blinded treatment phase, the combined inci-
dence, adjusted for years of patient follow-up, of positively
adjudicated ONJ for both trials was 49 (1.9 %) in the
denosumab group and 31 (1.2%) in the ZA group. The patient
incidence of ONJ during the open-label extension phase, not
adjusted for years of patient follow-up, was 32 (6.9 %) in the
denosumab/denosumab group and 25 (5.5 %) in the ZA/
denosumab group. Incidence by study is shown in Table 3.
Most of the events of ONJ in the open-label phases were mild
or moderate in severity and were treated conservatively. A
history of tooth extraction, poor oral hygiene, and/or use of a
dental appliance was documented in 53 (93 %) patients who
developed ONJ; tooth extractions accounted for 26 (49 %) of
these cases. For patients initially randomized to denosumab,
the median (Q1, Q3) time from blinded treatment initiation to
the onset of ONJ was 20.6 (14.0, 30.5) months overall for the
full study period in both studies combined. In the breast cancer
study, 37% received conservative treatment (mouth rinses and
antibiotics) and 63 % had limited surgical treatment (i.e.,
sequestrectomy, debridement, and curettage). In the prostate
cancer study, 47 % of patients had conservative management,
and 52 % had limited surgical treatments; one patient required
a partial maxillary resection.
Among all patients who developed ONJ across blinded and
open-label extension phases, 35/83 (42 %) patients in the
breast cancer study and 15/57 (26 %) in the prostate cancer
study had resolution of ONJ, defined as complete mucosal
coverage of exposed bone. The median (Q1, Q3) time to
ONJ resolution was 7.9 (3.4, 13.4) months in the
denosumab/denosumab and 9.2 (8.0, 16.7) months in the
ZA/denosumab groups for the breast cancer study, and 10.0
(5.3, 14.9) months and 13.0 (6.5, 23.2) months, respectively,
for the prostate cancer study. Eleven (13 %) and 22 (40 %)
patients in the breast and prostate cancer studies, respectively,
died before ONJ resolution.
For patients in the breast cancer study who received
denosumab throughout, the cumulative patient-year ad-
justed incidence of ONJ, including both the blinded and
open-label extension phases of the trial, was 2.5 % for a
median (Q1, Q3) (range) of 19.1 (9.2, 32.2) (0.1 to
59.8) months. A similar incidence of ONJ was noted
in patients who received denosumab throughout the
prostate cancer trial, with a cumulative incidence of
2.8 % with a median (Q1, Q3) (range) exposure to
denosumab of 12.0 (5.6, 21.3) (0.1–67.2) months.
Overall, for both studies, 18 patients (1.1 % per 100
patient-years, comprising 1602 total patient-years of fol-
low-up) and 11 patients (0.7 % per 100 patient-years,
comprising 1570 total patient-years follow-up) devel-
oped confirmed ONJ during the first year of denosumab
or ZA treatment, respectively. ONJ incidence rates ob-
served in the blinded treatment phases for the individual
trials are shown by time of onset in Fig. 2. Rates were
not significantly different between ZA and denosumab
groups for the first or subsequent years of treatment,
al though numbers were numerical ly higher for
denosumab at all time points. During subsequent years
Table 2 Cumulative exposure to denosumab in the open-label phase and over the entire study period
Median (Q1, Q3) [range] exposure, months Denosumab/Denosumab Zoledronic Acid/Denosumaba
Breast cancer study
(n = 1019)
Prostate cancer
study(n = 942)
Breast cancer study
(n = 1019)
Prostate cancer study
(n = 942)
Open-label extension phaseb
Full study (double-blinded and
open label phases)c
17.6 (8.3, 23.0)
[0–23.7]
(n = 318)
19.1 (9.2, 32.2)
[0.1–59.8]
12.0 (5.3, 22.1)
[0.1–23.3]
(n = 147)
12.0 (5.6, 21.3)
[0.1–67.2]
16.3 (7.4, 22.8)
[0.5–23.3]
(n = 334)
Open-label phase onlya
12.0 (5.5, 20.5)
[0.4–23.3]
(n = 118)
Open-label phase onlya
Q1, Q3 first and third quartiles
a Patients received denosumab in the open-label phase only
bDenosumab exposure in the open-label extension treatment phase only
c Cumulative denosumab exposure in the double-blinded and open-label extension phases for all randomized patients
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that included open-label treatment, 31 patients (4.1 %
per 100 patient-years, comprising 1616 patient-years of
follow-up) in the denosumab/denosumab group devel-
oped confirmed ONJ.
During the open-label extension phase of the breast
and prostate cancer trials, adverse events of hypocalce-
mia were observed at similar frequency comparing those
who continued with denosumab therapy (20 (4.3 %))
versus those who switched from ZA to denosumab
treatment (14 (3.1 %)). Overall, hypocalcemia rates dur-
ing the open-label phase were similar to slightly lower
compared with those observed in the blinded treatment
phase. Six patients in the denosumab/denosumab group
and five patients in the ZA/denosumab group had ad-
verse events of hypocalcemia requiring IV calcium ther-
apy; these events were considered serious in four and
one patients, respectively (Table 3). Among these, one
patient in each group had a baseline creatinine clearance
<60 mL/min; two patients in the ZA/denosumab group
and one in the denosumab/denosumab group did not
report oral vitamin D or calcium supplementation,
respectively. In the breast cancer study, there was 1
(0.3 %) Common Terminology Criteria for Adverse
Events (CTCAE; version 3) grade 4 hypocalcemia event
reported for each group, with no grade 3 events. In the
prostate cancer study, there were 3 (2.0 %) and 2
(1.7 %) CTCAE grade 3 hypocalcemia events reported
for the groups initially receiving denosumab and ZA,
respectively, and 1 (0.7) grade 4 event reported for the
denosumab group. No patients had symptoms associated
with severe hypocalcemia, nor were there any fatal ad-
verse events of hypocalcemia. Overall, the incidence of
hypocalcemia did not increase with increased exposure
to denosumab. The risk of hypocalcemia during the
open-label phase was not increased in patients who
switched from ZA to denosumab, or in those who had
impaired renal function.
Overall survival
Overall survival throughout the duration of the study was
similar between treatment groups for both trials (Fig. 3a, 3b).
Table 3 Adverse events during the open-label treatment phase
Event, n (%) Breast cancer study Prostate cancer study
Denosumab/Denosumab
(N = 318)a
Zoledronic Acid/Denosumab
(N = 334)a
Denosumab/Denosumab
(N = 147)a
Zoledronic Acid/
Denosumab (N = 118)a
All adverse events 283 (89.0) 303 (90.7) 138 (93.9) 105 (89.0)
Serious adverse events 126 (39.6) 133 (39.8) 78 (53.1) 63 (53.4)
Most common adverse events
Nausea 72 (22.6) 77 (23.1) 20 (13.6) 16 (13.6)
Anemia 3 (16.7) 50 (15.0) 34 (23.1) 26 (22.0)
Fatigue 70 (22.0) 74 (22.2) 23 (15.6) 15 (12.7)
Back pain 66 (20.8) 56 (16.8) 29 (19.7) 19 (16.1)
Asthenia 40 (12.6) 48 (14.4) 29 (19.7) 11 (9.3)
Arthralgia 57 (17.9) 61 (18.3) 25 (17.0) 17 (14.4)
Adverse events of infectionb 135 (42.5) 135 (40.4) 58 (39.5) 33 (28.0)
Osteonecrosis of the jaw (ONJ)c, d 20 (6.3) 18 (5.4) 12 (8.2) 7 (5.9)
CTCAE, v 3 grade 3 2 (0.6) 6 (1.8) 3 (2.0) 1 (0.8)
CTCAE, v 3 grade 4 0 (0.0) 1 (0.3) 0 (0.0) 1 (0.8)
Adverse events of new primary malignancye 2 (0.6)f 1 (0.3)g 1 (0.7)h 0 (0.0)
Adverse events of hypocalcemiai 12 (3.8) 9 (2.7) 8 (5.4) 5 (4.2)
Serious 3 (0.9) 0 (0.0) 1 (0.7) 1 (0.8)
CTCAE Common Terminology Criteria for Adverse Events; version 3
aNumber of patients who received at least one dose of open-label denosumab
b System organ class: Infections and Infestations, Medical Dictionary for Regulatory Activities version 14.0 (breast cancer study), 14.1 (prostate cancer
study)
c Positively adjudicated by blinded committee of experts. There were no grade 5 ONJ events
d Rates not adjusted for patient-years of investigational product exposure and patient follow-up
eNo events were considered by the investigator to be related to denosumab treatment
f Renal cell cancer, squamous cell carcinoma of the skin
gGerm cell cancer
h Bladder cancer
i Includes the preferred terms hypocalcemia and blood calcium decreased
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Discussion
In patients with metastatic cancers, SREs impair health-
related quality of life, decreasing functional capabilities
and increasing pain and opioid use [5]. With more effi-
cacious and targeted antitumor therapies, further im-
provements in overall survival are expected. Because
SRE risk increases with progression of metastatic dis-
ease [6, 7], maintaining quality of life by preventing
complications of bone metastases, including SREs and
hypercalcemia, remains a priority.
The long-term safety of IV bisphosphonates has not been
adequately studied in controlled trials, and concerns regarding
long-term complications including renal toxicity, ONJ, and
atypical femoral fractures remain a primary rationale for the
current practice of withholding therapy or implementing a less
intensive schedule of therapy after 1–2 years [8, 9]. Recent
trials designed to determine the optimal bisphosphonate dos-
ing based on serum or urinary markers of bone turnover have
experienced poor accrual and limitations in study design. This
has led to inconclusive results, with no clear support for a
decrease in toxicities or maintained efficacy for preventing
SREs with less frequent dosing schedules (Q12W [10], or
Q9W or Q16W [11]) or total number of doses administered
[12, 13]. The recently presented OPTIMIZE-2 trial also com-
pared Q12W with Q4W ZA therapy in patients with metasta-
tic breast cancer and bone metastases who had previously
received at least 1 year of monthly ZA [14]. Non-inferiority
in the 1-year SRE rate was reached in the study (95 %
CI: −7.5 to 9.8 %); however, study accrual was
amended secondary to poor accrual, and only 403 pa-
tients were ultimately randomized and followed for
1 year [14]. Additional trials including the CALGB
70604 trial [15] comparing Q12W with Q4W dosing
will provide additional data on the risk:benefit profile
associated with less intensive bisphosphonate schedules.
Denosumab is a fully human monoclonal antibody with a
half-life of several weeks [16] and is not eliminated via the
kidneys compared with bisphosphonates, which are primarily
eliminated renally, bind to hydroxyapatite, and may remain
Fig. 2 ONJ rates for the blinded treatment phases of the breast cancer and
prostate cancer trials during the first year of treatment, subsequent years
of treatment, and blinded treatment overall. Incidence rates are adjusted
for patient-years of follow-up to reflect different lengths of time on study,
and expressed per 100 patient-years of follow-up, calculated as a ratio of
the total number of adjudicated positive ONJ events and the total subject-
years of follow-up through either the end-of-study date or the blinded
treatment phase cutoff date. ONJ osteonecrosis of the jaw
*One additional patient in the zoledronic acid/denosumab group devel-
oped ONJ after the end-of-study date
Fig. 3 Kaplan-Meier estimates of overall survival for the duration of the breast (a) and prostate (b) cancer studies. KM Kaplan-Meier, Q1, Q3
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sequestered in bones for many years [17]. Beyond the previ-
ously described differences in clinical efficacy [2],
denosumab’s mechanism of action and its more rapid
reversibility may make the antibody a better option es-
pecially for patients susceptible to bisphosphonate-
related complications, or those with compromised renal
function. As with previous reports for patients who
switched from ZA treatment to denosumab treatment
[18], there were no apparent safety issues associated
with the change in treatment.
Additionally, the prolonged use of denosumab in
these patients for a median 19.1 months of Q4W thera-
py was associated with no newly identified safety sig-
nals, no unexpected toxicity, and no requirement for
dose reductions or changes in the dosing schedule. No
events of atypical femoral fractures were noted in the
three pivotal phase 3 denosumab trials in patients with
bone metastases from solid tumors. However, this com-
plication has been reported rarely in patients receiving
oral or IV bisphosphonates [19] and more recently with
denosumab at 60 mg every 6 months (Prolia®) [20] for
osteoporosis, as well as in one case following long-term
dosing with denosumab 120 mg Q4W (XGEVA®) in an
unapproved indication [21]. Thus, patients should be
informed regarding this potential risk with long-term
bone-targeted therapy.
Adverse events of ONJ and hypocalcemia were also ob-
served in the open-label treatment phase. The majority of ONJ
cases were associated with known risk factors involving inva-
sive dental procedures and poor oral hygiene [22]; and the
incidence rate increased with the duration of anti-resorptive
therapy [23, 24]. However, it should be noted that in the ab-
sence of bone-targeted therapy, SRE rates also increase over
time and occur at a rate that far exceeds ONJ [25, 26]. Hypo-
calcemia was similar in incidence between treatment groups,
manageable with appropriate therapy, and occurred at rates
similar to those reported in the double-blinded phases of the
studies. Few clinical trials have assessed the safety of potent
anti-resorptive agents in advanced cancer patients beyond
2 years. A retrospective study in women with metastatic breast
cancer who had received ZA or pamidronate for at least
24 months found that the rate of ONJ in these patients was
3.8 % [27]. This rate is similar to the 2.5 % rate reported for
breast cancer patients in our study who received denosumab in
both the blinded and open label treatment phases. The results
presented in this manuscript are important for confirming the
need to vigilantly follow patients for these known side effects
of bone-targeted therapies, even after prolonged availability
and administration of these agents. Patients should continue to
be counseled on the importance of dental hygiene and
preventive dentistry and adherence to calcium and vita-
min D supplements while receiving bone-targeted treat-
ment, particularly those with severe renal impairment
[28]. Healthcare providers should also ensure that pa-
tients receiving bone-targeted therapy are aware of the
symptoms associated with hypocalcemia, including mus-
cle stiffness, twitching, spasms, or cramps [21], and
should monitor these patients, including cardiac moni-
toring in patients with severe hypocalcemia.
In conclusion, data from the open-label extension
phase of two pivotal trials in metastatic breast and pros-
tate cancer, respectively, confirm the known safety pro-
file of denosumab with long-term administration for a
median 19.1 months (up to 5 years) in metastatic breast
cancer and a median 12.0 months (up to 5.6 years) in
metastatic prostate cancer. Additionally, there were no
new safety signals among patients who were switched
to denosumab therapy after continuous ZA treatment,
suggesting that changing from an IV bisphosphonate to
denosumab is a valid treatment strategy where clinically
indicated for patients with advanced breast and prostate
cancers [29].
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